Lyell Immunopharma (LYEL) PE Ratio: History & Chart

Lyell Immunopharma, Inc.(LYEL)

Biotechnology · South San Francisco, CA

$8.61-0.46 (-5.07%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

South San Francisco, CA

161 employees

www.lyell.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lynn Seely

View full financials

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Lyell Immunopharma, Inc. (LYEL)	$210.98M	N/A	N/A	N/A	N/A
Entrada Therapeutics, Inc. (TRDA)vs ›	$210.41M	N/A	8.07	11.31	11.31
Compugen Ltd. (CGEN)vs ›	$209.91M	5.91	6.53	42.60	42.60
Electra Therapeutics Inc. (ETRA)vs ›	$208.31M	N/A	N/A	N/A	N/A
Niagen Bioscience Inc (NAGE)vs ›	$214.24M	14.43	22.48	68.28	68.28
Sionna Therapeutics, Inc. (SION)vs ›	$214.46M	N/A	N/A	N/A	N/A
Pro-Dex, Inc. (PDEX)vs ›	$207.27M	15.76	14.32	17.96	17.40
Anbio Biotechnology Class A Ordinary Shares (NNNN)vs ›	$215.07M	N/A	N/A	N/A	N/A
Whitehawk Therapeutics Inc (WHWK)vs ›	$205.80M	N/A	399.45	399.45	399.45
Prelude Therapeutics Incorporated (PRLD)vs ›	$216.91M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PE RATIO

TTM

Lyell Immunopharma, Inc. (LYEL)

$210.98M

N/A

Entrada Therapeutics, Inc. (TRDA)vs ›

$210.41M

N/A

8.07

11.31

Compugen Ltd. (CGEN)vs ›

$209.91M

5.91

6.53

42.60

Electra Therapeutics Inc. (ETRA)vs ›

$208.31M

N/A

Niagen Bioscience Inc (NAGE)vs ›

$214.24M

14.43

22.48

68.28

Sionna Therapeutics, Inc. (SION)vs ›

$214.46M

N/A

Pro-Dex, Inc. (PDEX)vs ›

$207.27M

15.76

14.32

17.96

17.40

Anbio Biotechnology Class A Ordinary Shares (NNNN)vs ›

$215.07M

N/A

Whitehawk Therapeutics Inc (WHWK)vs ›

$205.80M

N/A

399.45

Prelude Therapeutics Incorporated (PRLD)vs ›

$216.91M

N/A

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio: N/A

LYEL PE Ratio Metrics

LYEL Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics